Genetic Analysis of Liver Cancer

This study has been terminated.
(low accrual)
Information provided by (Responsible Party):
Samuel So, Stanford University Identifier:
First received: October 3, 2008
Last updated: January 30, 2012
Last verified: January 2012
Liver cancer is a leading cause of cancer deaths worldwide. While the molecular pathogenesis of liver cancer has been extensively studied, less is known about how the molecular biology of liver cancer influences clinical outcome and treatment response. We are developing a translational research program that will characterize molecular changes in liver cancer. We plan to use molecular information obtained from studying liver tumor tissues to develop new diagnostics and treatment regimens for patients with these cancers. The experimental approach will require freezing fresh tumor tissues obtained from surgical procedures, which will be subsequently used for analysis of DNA, protein and mRNA expression. Many patients with liver cancer are referred to the Stanford Liver Tumor Board for consultation and treatment recommendations. We propose to gather tissue samples from those who subsequently undergo biopsy, liver resection surgery, or transplant surgery.

Liver Cancer
Hepatitis B
Hepatitis C
Hepatobiliary Cancers
Hepatobiliary Cancers Liver

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Genetic Analysis of Liver Cancer

Resource links provided by NLM:

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples With DNA
tumor sample

Enrollment: 41
Study Start Date: June 2008
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
liver cancer patients

Inclusion Criteria:3.1.1 Male or female patients 18 years of age and above. 3.1.2 Patients diagnosed with liver cancer based on biopsy or serum alpha-fetoprotein level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. Patients with metastatic tumor from anther organ, such as metastatic colon cancer.

3.13 Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:3.2.1Female patients who are pregnant or nursing will be excluded from the study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00768001

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Samuel So
Principal Investigator: Samuel So Stanford University
  More Information

Responsible Party: Samuel So, Professor of Medicine, Stanford University Identifier: NCT00768001     History of Changes
Other Study ID Numbers: HEP0012  98717 
Study First Received: October 3, 2008
Last Updated: January 30, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hepatitis A
Liver Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Enterovirus Infections
Hepatitis, Viral, Human
Liver Diseases
Neoplasms by Site
Picornaviridae Infections
RNA Virus Infections
Virus Diseases processed this record on May 25, 2016